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The purpose of this research is to determine whether anti-resorptive pharmaceuticals such as
bisphosphonates, in conjunction with the routine in-flight exercise program, will protect ISS crewmembers
from the regional decreases in bone mineral density and bone strength and the increased renal stone risk
documented on previous long-duration space flights [1-3]. Losses averaged ~ 1 to 2 percent per month in
such regions as the lumbar spine and hip. Although losses showed significant heterogeneity among
individuals and between bones within a given subject, space flight-induced bone loss was a consistent
finding. More than 90 percent of astronauts and cosmonauts on long-duration flights (average 171 days)
aboard Mir and the ISS, had a minimum 5 percent loss in at least one skeletal site, 40 percent of them had a
10 percent or greater loss in at least one skeletal site, and 22 percent of the Mir cosmonauts experienced a
15 to 20 percent loss in at least one site. These losses occurred even though the crewmembers performed
time-consuming in-flight exercise regimens. Moreover, a recent study of 16 ISS astronauts using
quantitative computed tomography (QCT) demonstrated trabecular bone losses from the hip averaging 2.3
percent per month [4]. These losses were accompanied by significant losses in hip bone strength that may
not be recovered quickly [5].
This rapid loss of bone mass results from a combination of increased and uncoupled remodeling, as
demonstrated by increased resorption with little or no change in bone formation markers [6-7]. This
elevated remodeling rate likely affects the cortical and trabecular architecture and may lead to irreversible
changes. In addition to bone loss, the resulting hypercalciuria increases renal stone risk. Therefore, it is
logical to attempt to attenuate this increased remodeling with anti-resorption drugs such as
bisphosphonates. Success with alendronate was demonstrated in a bed rest study [8]. This work has been
extended to space flight and two dosing regimens: 1) an oral dose of 70 mg of alendronate taken weekly
during flight or 2) a single intravenous (IV) dose of 4 mg of zoledronic acid given several weeks before
flight. Currently the study is focusing on the oral option because of NASA’s safety concerns with the IV-
administered drug. The protocol requests 10 male or female crewmembers on ISS flights of 90 days or
longer. Controls are 16 previous ISS crewmembers with QCT scans of the hip performed by these same
investigators. The primary outcome measure for this study is hip trabecular bone mineral density measured
by QCT, but other measures of bone mass are performed including peripheral QCT (pQCT) and dual-
energy x-ray absorptiometry. Serum and urinary bone markers and renal stone risk measured before,
during, and after flight are included. Postflight data are currently being collected from 2 ISS crewmembers.
Two additional crewmembers will return this spring after ~6-month missions. To date no untoward effects
have been encountered.
If it is successful, treatment with bisphosphonate or other anti-resorptive agents could be used to
supplement other countermeasures such as exercise. Drug therapy would be particularly important when
exercise cannot be used effectively, as after injury or equipment malfunction, or when other crew or
equipment constraints limit exercise. Use of a pharmaceutical countermeasure as well as exercise could
reduce the amount of time that must be spent on exercise (that is, could increase efficiency) without
requiring significant additional hardware, storage space, or cost.
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